why choose us

First received: June 20, 2023

Clinical Trial: Immunogenicity and Safety of Comvigen (Bivalent) Vaccine

Study Status: Completed

Recruit Status: RECRUITING

Condition: Safety of a Single Dose of COMVIGEN Vaccine

Study Type: INTERVENTIONAL


Official Title: A Phase 2, Non-inferiority, Open-label, Randomized Controlled Study to Evaluate the Immunogenicity and Safety of Comvigen (Bivalent) Vaccine as a Booster Dose in Adults Who Have Received a Previous Bo

Brief Summary: This study will assess the safety, reactogenicity and immunogenicity of a single dose of Comvigen (Bivalent, ChulaCov19 BNA159.2) vaccine or BIVALENT Pfizer/BNT vaccine as a booster among healthy males and non-pregnant females aged 18-64 years after receiving a previous booster dose of any approved mRNA COVID-19 vaccine for more than 3 months.The results of Combiven will be compared to BIVALENT Pfizer/BNT vaccine.

Read more